Outsourcing is becoming increasingly popular in biomanufacturing. As a time-consuming and resource-hungry unit operation, buffer preparation is often one of the first elements targeted for consideration.
Whilst the popularity of outsourcing buffer preparation is increasing, it won’t always be the right choice. The opportunities offered by outsourcing are inevitably accompanied by some concerns.
Freeing up the time of your highly trained staff by moving them away from labour-intensive process steps, could be just the boost you need.
The arrival of more complex biologics, such as antibody fragments, antibody drug conjugates (ADCs) and bispecifics, can increase the complexity of the biomanufacturing process requirements.
Traditionally, manufacturers of biologics have relied on in-house production of buffers. But an increasing trend has been emerging in the industry over the last six years: outsourcing.
Yes, outsourcing buffer preparation is advantageous for large-scale operations, but it also has its place in smaller processes e.g. in research or cell and gene therapy applications.
Perhaps the most well-recognised advantage of outsourcing buffer preparation is the extra facility capacity that is freed up as a result of removing your in-house capabilities.
The decision whether or not to outsource buffer preparation is not clear-cut, but provides an opportunity to balance risk with reward